Reportlinker Adds Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
NEW YORK, Jan. 4 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
THIS REPORT:
Focus on the background and the current state of disease-modifying and treatment-of-symptoms therapeutics, and the diagnostics global market segments
Provide global market data for 2008, estimates for 2009, and forecasts, with compound annual growth rates (CAGRS), through 2014
Discuss the increasingly difficult challenges that caregivers, families and the healthcare industry face as the number of patients climbs and the frustration with the lack of effective treatments grows
Review treatments in development and quantify the opportunities in the Alzheimer's disease market
Offer detailed company profiles and patent analyses.
Chapter- 1: INTRODUCTION -- Complimentary
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THIS STUDY 1
SCOPE OF REPORT 1
INTENDED AUDIENCE 2
METHODOLOGY 2
INFORMATION SOURCES 2
ANALYST CREDENTIALS 2
RELATED BCC REPORTS 2
BCC ONLINE SERVICES 3
DISCLAIMER 3
Chapter-2: SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, THROUGH 2014 ($ MILLIONS) 4
SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, 2008-2014 ($ MILLIONS) 4
FORECAST SUMMARY 5
Chapter-3: OVERVIEW
DEFINITION AND MARKET STRUCTURE 6
WHAT IS ALZHEIMER'S DISEASE? 6
TABLE 1 U.S. ALZHEIMER'S PATIENTS, 2000-2050 (MILLIONS) 6
FIGURE 1 U.S. ALZHEIMER'S PATIENTS, 2000-2050 (MILLIONS) 7
Role of the Cholinergic System 7
Role of Beta-Amyloid Protein 8
Behavioral Manifestations of AD 9
INCIDENCE AND PREVALENCE 9
TABLE 2 POPULATION BY SELECTED GEOGRAPHIC REGION, 2009-2050 (MILLIONS) 9
TABLE 3 PERCENT POPULATION OVER 65, BY REGION (%) 10
TABLE 4 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS) 10
FIGURE 2 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS) 10
TABLE 5 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET 11
FIGURE 3 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET (%) 11
TABLE 6 GLOBAL DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%) 12
STAGES OF ALZHEIMER'S DISEASE 12
Stages of Alzheimer's ... (Continued) 13
DIAGNOSIS 14
TABLE 7 DIAGNOSTIC TESTS 15
How Accurate are the Screening Tests? 16
KEY EVENTS 17
PATENT EXPIRATIONS 17
NEW PRODUCT LAUNCHES 18
PRICING 18
KEY MARKETS 18
TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, THROUGH 2014 ($ MILLIONS) 18
FIGURE 4 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2008-2014 ($ MILLIONS) 19
MARKET SIZE AND KEY PLAYERS 19
THERAPEUTICS 20
TABLE 9 EXISTING TREATMENTS: ALZHEIMER'S DISEASE 20
TABLE 10 GLOBAL EXISTING MARKET FOR SYMPTOM-ADDRESSING ALZHEIMER'S DISEASE, BY TYPE, 2002-2009 ($ MILLIONS) 20
TABLE 10 (CONTINUED) 21
TABLE 11 GLOBALMARKET FOR ALZHEIMER'S DRUG CLASSES BY GEOGRAPHICAL REGION (U.S., EUROPE, JAPAN), 2009 ESTIMATED ($ MILLIONS) 21
TABLE 12 TYPES OF DRUGS USED TO TREAT ALZHEIMER'S DISEASE 21
TABLE 13 MARKET SHARE OF EXISTING THERAPEUTICS FOR ALZHEIMER'S DISEASE, 2008 22
TABLE 14 BREAKDOWN OF TREATMENT MARKET BY DISEASE SEVERITY (%) 22
TABLE 15 DEMENTIA RATE BY UNDERLYING DISEASE STATE (%) 23
TABLE 16 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%) 23
TABLE 17 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, THROUGH 2014 ($ MILLIONS) 24
FIGURE 5 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, 2007-2014 ($ MILLIONS) 24
TABLE 18 GLOBAL POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS, THROUGH 2014 ($ MILLIONS) 24
TABLE 18 (CONTINUED) 25
FIGURE 6 GLOBAL MEMORY/COGNITION THERAPEUTICS MARKET BY DISEASE AREA, 2008 (%) 25
Key Players 26
TABLE 19 MARKET SHARE OF TOP COMPANIES WORKING IN MEMORY AND COGNITION (%) 26
TABLE 20 MARKETED TREATMENTS: ALZHEIMER'S DISEASE 26
TABLE 20 (CONTINUED) 27
Drivers 27
Issues and Challenges 27
IMAGING AND DIAGNOSTICS 27
Current Use in Alzheimer's Disease 27
Current Use in ... (Continued) 28
Diagnostic Testing Segments 29
Imaging 29
TABLE 21 IMAGING MARKET, 2008 ($ MILLIONS) 30
FIGURE 7 IMAGING MARKET, 2008 ($ MILLIONS) 30
Standardization Needed 30
Diagnostics 31
Novel Imaging Agents 32
Opportunities for Biomarkers in AD 33
TABLE 22 BIOMARKERS FOR ALZHEIMER'S DISEASE 34
TABLE 22 (CONTINUED) 35
TABLE 23 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, THROUGH 2014 ($ MILLIONS) 36
FIGURE 8 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, 2008-2014 ($ MILLIONS) 36
Opportunities for ... (Continued) 37
Opportunities for ... (Continued) 38
TABLE 24 U.S. CLINICAL TRIAL MARKET FOR BIOMARKERS BY PHASE--NUMBER OF TRIALS, PATIENTS, BIOMARKER PATIENTS, COST PER TEST, MARKET SIZE, 2008 39
TABLE 25 CLINICAL TRIAL MARKET FOR BIOMARKERS BY GEOGRAPHICAL REGION, 2008 ($ MILLIONS) 39
Testing Hypotheses 40
Diagnostic Tests 40
Diagnostic Tests (Continued) 41
Key Players 42
Agilent Technologies 42
Bioscan 42
Capintec Inc. 43
Digirad Corporation 43
Gamma Medica-Ideas 43
GE Healthcare 44
Hitachi Medical Systems America Inc. 44
Nymox 44
OptoSonics Inc. 45
Philips Healthcare 46
Positron Corp. 46
Siemens Healthcare 47
Spectrum Dynamics Ltd. 47
Toshiba Medical Systems 48
UltraSPECT Ltd. 48
VisEn Medical Inc. 48
Zecotek Imaging Systems 49
Drivers 49
Issues and Challenges 49
SWOT ANALYSIS 50
TABLE 26 SWOT ANALYSIS OF EXISTING ALZHEIMER'S DISEASE MARKET AND PLAYERS 50
Chapter-4: TECHNOLOGIES AND APPLICATIONS
COMMON MECHANISMS OF ACTION 51
CHOLINESTERASE INHIBITORS 52
TABLE 27 CHOLINESTERASE INHIBITORS 52
TABLE 28 PRODUCT SIDE EFFECT COMPARISON (%) 53
FIGURE 9 PRODUCT SIDE EFFECT COMPARISON (%) 53
TABLE 29 VACCINES 54
TABLE 30 ANTI-OXIDANTS 54
NMDA ANTAGONISTS 54
TABLE 31 NMDA ANTAGONISTS 55
NICOTINICS 55
TABLE 32 NICOTINIC ACETYLCHOLINE ANTAGONISTS 56
CALCINEURINS 56
TABLE 33 CALCINEURINS 56
GABA MODULATORS 56
TABLE 34 ANTI-EPILEPTIC/GABA MODULATORS 57
HORMONES 57
TABLE 35 HORMONES 58
OTHER THERAPEUTIC MECHANISMS 58
TABLE 36 OTC TREATMENTS/NATURAL PRODUCTS 59
IMAGING AND DIAGNOSTICS--MODALITIES AND APPLICATIONS 59
IMAGING AND DIAGNOSTICS...(CONTINUED) 60
NUCLEAR MEDICINE 61
Positron Emission Tomography (PET) 61
Single Photon Emission Computed Tomography (SPECT) 62
Gamma Cameras 63
CT (COMPUTED TOMOGRAPHY) 63
DEXA 63
MRI (MAGNETIC RESONANCE IMAGING) 64
ULTRASOUND 65
X-RAY 65
FUSION IMAGING 66
PET/CT 66
SPECT/CT 67
SPECT-CT in Cardiology 67
SPECT-CT in General Nuclear Medicine 68
SPECT-CT in Neurology 68
DIAGNOSTIC IMAGING IN ALZHEIMER'S 69
DISEASE-MODIFYING VS. TREATMENT OF SYMPTOMS 70
SYMPTOMATIC RELIEF--LIFE-CYCLE MANAGEMENT OF EXISTING PRODUCTS 71
OTHER DRUGS TARGETING SYMPTOMATIC RELIEF 71
DRUG RE-PURPOSING 72
GENERICS 72
Chapter-5: WORLDWIDE INDUSTRY STRUCTURE
GROWTH DRIVERS 73
AGING POPULATION 73
OFF-LABEL USE 74
UNDERSTANDING OF MECHANISMS 75
Transcranial Magnetic Stimulation 76
Genetic Modifications 76
GROWTH OBSTACLES 77
UNDERSTANDING OF MECHANISMS 77
TABLE 37 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 78
CO-MORBID DISEASE STATES 78
KEY COMPETITIVE FACTORS 78
PRODUCT LAUNCH 79
LIFE CYCLE MANAGEMENT 79
PAYORS 79
Payors (Continued) 80
INTERNATIONAL ASPECTS 81
TABLE 38 PERCAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY, THROUGH 2006 ($ MILLIONS) 82
INTERNATIONAL ASPECTS (CONTINUED) 83
Chapter-6: LEGISLATION AND REGULATORY ENVIRONMENT
VALIDATED TARGETS 84
LACK OF BIOMARKERS 84
TRANSLATIONAL MEDICINE 85
REIMBURSEMENT 86
Chapter-7: RELATED DEALS AND PARTNERSHIPS
APPROACH 87
DIAGNOSTICS DEALS 88
OVERALL ACTIVITY 88
TABLE 39 RELATED DEALS AND PARTNERSHIPS, 2004-2009 89
TABLE 39 (CONTINUED) 90
TABLE 39 (CONTINUED) 91
Chapter-8: PIPELINE
PIPELINE 92
TABLE 40 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS, BY PHASE 93
TABLE 40 (CONTINUED) 94
TABLE 40 (CONTINUED) 95
TABLE 40 (CONTINUED) 96
TABLE 40 (CONTINUED) 97
TABLE 40 (CONTINUED) 98
FIGURE 10 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS: NUMBER OF PROGRAMS AT EACH CLINICAL PHASE 98
FIGURE 10 (CONTINUED) 99
Chapter-9: TRENDS AND CHALLENGES
AWARENESS OF ALZHEIMER'S 100
DISEASE PATHWAYS BEING ELUCIDATED 100
MANY PROGRAMS IN DEVELOPMENT 101
TABLE 41 SOME NOT-FOR-PROFIT ORGANIZATIONS AND CONSORTIA IN THE AD AREA 101
MANY PROGRAMS IN DEVELOPMENT (CONTINUED) 102
TABLE 42 INVESTMENT IN ALZHEIMER'S DISEASE COMPANIES 103
Chapter-10: OUTLOOK
A VARIETY OF APPROACHES IN RESEARCH 104
MANY PROGRAMS IN DEVELOPMENT 105
Chapter-11: PATENT ANALYSIS
TABLE 43 KEY PATENT EXPIRY--ALZHEIMER'S THERAPEUTICS, BY CATEGORY 106
TABLE 44 MAJOR U.S. PATENT HOLDERS/FILERS IN ALZHEIMER'S THERAPEUTICS AND TECHNOLOGIES 107
TABLE 45 PATENT APPLICATIONS (U.S.) 107
TABLE 45 (CONTINUED) 108
TABLE 45 (CONTINUED) 109
TABLE 45 (CONTINUED) 110
TABLE 45 (CONTINUED) 111
TABLE 45 (CONTINUED) 112
TABLE 45 (CONTINUED) 113
TABLE 45 (CONTINUED) 114
TABLE 45 (CONTINUED) 115
TABLE 45 (CONTINUED) 116
TABLE 45 (CONTINUED) 117
TABLE 45 (CONTINUED) 118
TABLE 45 (CONTINUED) 119
TABLE 45 (CONTINUED) 120
TABLE 46 ISSUED PATENTS (U.S.) 120
TABLE 46 (CONTINUED) 121
TABLE 46 (CONTINUED) 122
TABLE 46 (CONTINUED) 123
TABLE 46 (CONTINUED) 124
TABLE 46 (CONTINUED) 125
TABLE 46 (CONTINUED) 126
TABLE 46 (CONTINUED) 127
TABLE 46 (CONTINUED) 128
TABLE 46 (CONTINUED) 129
TABLE 46 (CONTINUED) 130
TABLE 46 (CONTINUED) 131
Chapter-12: COMPANY PROFILES
ABLYNX 132
ACCERA, INC. 132
ACUMEN PHARMACEUTICALS 133
AFFIRIS AG 133
AFFITECH AS 134
ALLON THERAPEUTICS (FKA NEURODISCOVERY) 134
ALZHYME PTY 135
ASTELLAS 135
ASTRAZENECA 136
ATHENA DIAGNOSTICS (THERMO FISHER) 136
AVERA PHARMACEUTICALS 137
BAXTER HEALTHCARE 137
BAYER SCHERING PHARMA 138
BELLUS HEALTH 138
BIOFUTURA 139
BIOMERIEUX 139
BIOVAIL 140
BOEHRINGER INGELHEIM 140
BRACCO 140
BRAINCELLS, INC. 140
BRISTOL MYERS SQUIBB 141
CELLZOME 141
CEREGENE 142
COGNITION PHARMACEUTICALS LLC 142
COGNITION THERAPEUTICS 142
COLUCID PHARMACEUTICALS 143
COMENTIS 143
CORTEX PHARMACEUTICALS 144
C2N DIAGNOSTICS 144
CYTOS BIOTECHNOLOGY 145
DAIICHI SANKYO 145
DEBIOPHARM 146
DURECT 146
EISAI 146
ELAN 147
ELI LILLY 147
ENVIVO PHARMACEUTICALS 148
ESTEVE 148
EVOTEC 149
EXONHIT THERAPEUTICS 149
FOREST LABORATORIES 150
GALANTOS PHARMA 150
GALENEA 151
GE HEALTHCARE 151
GLAXOSMITH KLINE 152
HELICON THERAPEUTICS 152
INTELLECT NEUROSCIENCES 153
INTRA-CELLULAR THERAPIES 153
INVERNESS MEDICAL INNOVATIONS 154
IPSEN 154
JOHNSON & JOHNSON 155
KEYNEUROTEK 155
LEXICON PHARMACEUTICALS 155
LINK MEDICINE 156
LUNDBECK 156
MEDIVATION 157
MEMORY PHARMACEUTICALS 157
MERCK 158
MERCKSERONO 158
MERZ PHARMA 158
MITHRIDION 159
MITSUBISHI TANABE 159
MORPHOSYS 160
MP BIOMEDICALS 161
NEUREN PHARMACEUTICALS 161
NEUROPTIX 162
NEUROSEARCH 163
NEURO-HITECH 163
NEWRON PHARMACEUTICALS 163
NOSCIRA SA 164
NOVARTIS 165
NYMOX 165
OLIGOMERIX 166
ORTHO-MCNEIL NEUROLOGICS 166
PFIZER 166
POWER3 MEDICAL PRODUCTS 167
PRANA BIOTECHNOLOGY 167
PROTEOTECH INC. 168
PSYCHOGENICS 168
ROCHE 168
SAMARITAN PHARMACEUTICALS 169
SANOFI-AVENTIS 170
SATORI PHARMACEUTICALS 170
SATORIS 170
SCIELE PHARMA 171
SIEMENS MEDICAL SOLUTIONS 171
SOLVAY 172
SUVEN LIFE SCIENCE 172
TAKEDA 173
TARGACEPT 173
TAURX THERAPEUTICS 173
TAUTATIS 174
TEIKOKU 175
TEVA PHARMACEUTICALS 175
TRANSTECH PHARMA 175
VOYAGER PHARMACEUTICAL / DURAMED 176
WATSON PHARMACEUTICALS 176
WYETH/PFIZER 177
To order this report:
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article